Impact of Bivalirudin on Ischemia/Reperfusion Injury in Patients with Reperfused STEMI Assessed by Cardiac Magnetic Resonance
Zhang Y, Zou Z, Xu B, Chen B, Ge H, Ding S, Pu J (2024) · Pharmaceuticals · n=42
Studienprofil
- Design
- small prospective comparative study (n=42) of bivalirudin vs unfractionated heparin in primary PCI for STEMI patients, with serial cardiac magnetic resonance imaging at acute, 1-month, and 3-month follow-up; EARLY Assessment of Myocardial Tissue Characteristics by CMR in STEMI registry (NCT03768453, Shanghai Renji Hospital)
- Stichprobengröße (n)
- 42
- Intervention
- Bivalirudin (n=21) for STEMI primary PCI anticoagulation
- Komparator
- Unfractionated heparin (n=21) for STEMI primary PCI anticoagulation
- Primärer Endpunkt
- Myocardial edema volume, microvascular obstruction (MVO) volume/incidence, and intramyocardial hemorrhage (IMH) incidence on CMR
- Primäres Ergebnis
- Bivalirudin group: significantly less acute myocardial edema; only 4.7% had edema at 1 month vs 33.3% in heparin group; complete edema resolution by 3 months vs persistence in heparin group; significantly lower MVO incidence/volume acutely; significantly lower IMH incidence acutely and at follow-up; corroborated by T2/T1 mapping; bivalirudin associated with attenuated ischemia/reperfusion injury
- Follow-up-Dauer
- 3 months (serial CMR)
- PMID
- 38399411
Wichtigste Ergebnisse
- CMR-quantified myocardial edema, MVO, and IMH all significantly reduced with bivalirudin vs heparin
- Bivalirudin appears to reduce ischemia/reperfusion injury at the tissue level
- First imaging-endpoint corroboration of bivalirudin tissue-protective effects in STEMI
- n=21 per arm — small but adequately powered for primary CMR endpoints
- Reinforces drug-pathway development of synthetic hirudin derivatives
Einschränkungen
- Small sample (n=42 total)
- Single-center registry-based design
- Open-label (no blinding)
- Outcomes are imaging surrogates, not hard clinical endpoints
- Not generalizable beyond STEMI patient population
Klinische Implikationen
Zhang 2024 adds imaging-based mechanistic evidence to the bivalirudin literature. For ASH, the trial serves as a pharmacology and regulatory reference for distinguishing FDA-approved synthetic hirudin-derivative drug indications (bivalirudin in STEMI) from the K040187 device indication (whole-leech hirudotherapy in microsurgical flap salvage). Not directly applicable to US hirudotherapy clinical practice.
Verwandte Studien
Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification
Merlino G, Carbone S, Servillo G, Marletta DA (2020)
Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial
Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)
Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review
Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)
Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction
Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)